115 related articles for article (PubMed ID: 37503077)
1. Cooperative Genomic Lesions in HRAS-Mutant Cancers Predict Resistance to Farnesyltransferase Inhibitors.
Nigam A; Krishnamoorthy G; Chatila W; Berman K; Saqcena M; Walch H; Ho A; Schultz N; Fagin J; Untch B
Res Sq; 2023 Jul; ():. PubMed ID: 37503077
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Inhibition of ERK and Farnesyltransferase Suppresses the Growth of HRAS Mutant Head and Neck Squamous Cell Carcinoma.
Javaid S; Schaefer A; Goodwin CM; Nguyen VV; Massey FL; Pierobon M; Gambrell-Sanders D; Waters AM; Lambert KN; Diehl JN; Hobbs GA; Wood KC; Petricoin EF; Der CJ; Cox AD
Mol Cancer Ther; 2022 May; 21(5):762-774. PubMed ID: 35247914
[TBL] [Abstract][Full Text] [Related]
3. Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.
Untch BR; Dos Anjos V; Garcia-Rendueles MER; Knauf JA; Krishnamoorthy GP; Saqcena M; Bhanot UK; Socci ND; Ho AL; Ghossein R; Fagin JA
Cancer Res; 2018 Aug; 78(16):4642-4657. PubMed ID: 29760048
[TBL] [Abstract][Full Text] [Related]
4. Anchorage-independent growth conditions reveal a differential SOS2 dependence for transformation and survival in
Sheffels E; Sealover NE; Theard PL; Kortum RL
Small GTPases; 2021 Jan; 12(1):67-78. PubMed ID: 31062644
[TBL] [Abstract][Full Text] [Related]
5. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers.
Wee S; Jagani Z; Xiang KX; Loo A; Dorsch M; Yao YM; Sellers WR; Lengauer C; Stegmeier F
Cancer Res; 2009 May; 69(10):4286-93. PubMed ID: 19401449
[TBL] [Abstract][Full Text] [Related]
6. Tipifarnib as a Precision Therapy for
Gilardi M; Wang Z; Proietto M; Chillà A; Calleja-Valera JL; Goto Y; Vanoni M; Janes MR; Mikulski Z; Gualberto A; Molinolo AA; Ferrara N; Gutkind JS; Burrows F
Mol Cancer Ther; 2020 Sep; 19(9):1784-1796. PubMed ID: 32727882
[TBL] [Abstract][Full Text] [Related]
7. Transformation by Hras(G12V) is consistently associated with mutant allele copy gains and is reversed by farnesyl transferase inhibition.
Chen X; Makarewicz JM; Knauf JA; Johnson LK; Fagin JA
Oncogene; 2014 Nov; 33(47):5442-9. PubMed ID: 24240680
[TBL] [Abstract][Full Text] [Related]
8. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
9. Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcoma.
Odeniyide P; Yohe ME; Pollard K; Vaseva AV; Calizo A; Zhang L; Rodriguez FJ; Gross JM; Allen AN; Wan X; Somwar R; Schreck KC; Kessler L; Wang J; Pratilas CA
Oncogene; 2022 May; 41(21):2973-2983. PubMed ID: 35459782
[TBL] [Abstract][Full Text] [Related]
10. Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.
Hou W; Liu J; Chen P; Wang H; Ye BC; Qiang F
Oncol Lett; 2014 Sep; 8(3):1249-1254. PubMed ID: 25120700
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
[TBL] [Abstract][Full Text] [Related]
12.
Coleman N; Marcelo KL; Hopkins JF; Khan NI; Du R; Hong L; Park E; Balsara B; Leoni M; Pickering C; Myers J; Heymach J; Albacker LA; Hong D; Gillison M; Le X
JCO Precis Oncol; 2023 Jan; 7():e2200211. PubMed ID: 36603172
[TBL] [Abstract][Full Text] [Related]
13. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Hanna GJ; Guenette JP; Chau NG; Sayehli CM; Wilhelm C; Metcalf R; Wong DJ; Brose M; Razaq M; Pérez-Ruiz E; Cohen EEW; Aggarwal R; Scholz C; Gualberto A; Ho AL
Cancer; 2020 Sep; 126(17):3972-3981. PubMed ID: 32557577
[TBL] [Abstract][Full Text] [Related]
14. ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition.
Ruicci KM; Pinto N; Khan MI; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Nichols AC
Oral Oncol; 2018 Sep; 84():95-103. PubMed ID: 30115483
[TBL] [Abstract][Full Text] [Related]
15. A Phase II Trial of Tipifarnib for Patients with Previously Treated, Metastatic Urothelial Carcinoma Harboring
Lee HW; Sa JK; Gualberto A; Scholz C; Sung HH; Jeong BC; Choi HY; Kwon GY; Park SH
Clin Cancer Res; 2020 Oct; 26(19):5113-5119. PubMed ID: 32636318
[TBL] [Abstract][Full Text] [Related]
16. Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases.
Zhao Y; Yu H; Ida CM; Halling KC; Kipp BR; Geiersbach K; Rumilla KM; Gupta S; Lin MT; Zheng G
JAMA Netw Open; 2021 Jan; 4(1):e2035479. PubMed ID: 33507258
[TBL] [Abstract][Full Text] [Related]
17. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis.
To MD; Rosario RD; Westcott PM; Banta KL; Balmain A
Oncogene; 2013 Aug; 32(34):4028-33. PubMed ID: 22945650
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
[TBL] [Abstract][Full Text] [Related]
19. Mutant HRAS as novel target for MEK and mTOR inhibitors.
Kiessling MK; Curioni-Fontecedro A; Samaras P; Atrott K; Cosin-Roger J; Lang S; Scharl M; Rogler G
Oncotarget; 2015 Dec; 6(39):42183-96. PubMed ID: 26544513
[TBL] [Abstract][Full Text] [Related]
20. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation.
Bentley C; Jurinka SS; Kljavin NM; Vartanian S; Ramani SR; Gonzalez LC; Yu K; Modrusan Z; Du P; Bourgon R; Neve RM; Stokoe D
Biochem J; 2013 Jun; 452(2):313-20. PubMed ID: 23496764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]